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Background: Cervical cancer is the second most common cancer among women in Brazil. We examined the
health and economic impacts of quadrivalent HPV vaccination in Brazil.
Methods: We adapted a previously developed transmission dynamic model to estimate the effectiveness of HPV
vaccination on cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1, and genital warts.
We evaluated following vaccination strategies: routine vaccination of 12-year-old girls and routine vaccination in
combination with a catch-up vaccination of 12 to 26-year-old women.
Results: The model projected that the vaccination would reduce the incidence rates of HPV 6/11/16/18-related
cervical cancer, CIN2/3, CIN1, and female genital warts by 94% to 98% at year 100. Routine vaccination in
combination with a catch-up vaccination could prevent approximately 163,000 cases of cervical cancer, 48,000
deaths from cervical cancer, 2.3 million cases of CIN2/3, and 11.4 million genital warts in the next 50 years. The
incremental cost-effectiveness ratios for female vaccination strategies ranged from R$350 to R$720 (US$219 to
US$450) per quality-adjusted life year (QALY) gained.
Conclusions: Our study demonstrates that quadrivalent HPV female vaccination can be a cost-effective public
health intervention that can substantially reduce the burden of cervical diseases and genital warts in Brazil.Background
Every year, nearly 530,000 women develop cervical can-
cer and 275,000 die from the disease worldwide [1].
About 88% of deaths from cervical cancer occur in
developing countries [1]. Human papillomavirus (HPV)
is the primary cause of cervical cancer, with HPV-types
16 and 18 causing approximately 70% of cases globally
[2]. A quadrivalent HPV vaccine against HPV-types 6,
11, 16, and 18 (GardasilW by Merck & Co., Inc.) was re-
cently developed and is widely available around the
world [3-5].
Cervical cancer is the second most common cancer
among women in Brazil. The cervical cancer incidence
rate is two to three times higher in Brazil (19.2 per
100,000 women every year) than in North America and
Europe [6]. The quadrivalent HPV vaccine was approved
for use in Brazil to prevent cervical, vulvar, and vaginal* Correspondence: kkawai8@gmail.com
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reproduction in any medium, provided the orcancer, precancerous lesions, and genital warts caused
by HPV types 6, 11, 16, and 18. However, HPV vaccin-
ation has not been introduced as a national program in
Brazil. Understanding the health and economic impacts
of HPV vaccination is essential for policy makers to
make decisions regarding the introduction of national
vaccination programs. Previous cost-effectiveness studies
of HPV vaccination in Brazil and other middle-income
countries have used a range of different methods [7-11].
Because the mathematical transmission dynamic model
is required to describe the transmission of HPV infec-
tions and diseases, we used this method to examine the
effectiveness of HPV vaccination.
The purpose of our study was to examine the long-
term health and economic impacts of quadrivalent HPV
vaccination in Brazil using a transmission dynamic
model. We evaluated the following vaccination strat-
egies: routine vaccination of 12-year-old girls and rou-
tine vaccination of 12-year-old girls in combined with a
catch-up vaccination of 12 to 26-year-old women.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We adapted a previously developed transmission dynamic
model to evaluate the health and economic impacts of
HPV vaccination in Brazil [12]. The transmission dynamic
model incorporates the direct and indirect benefits (herd
immunity) of vaccination. Details of the model have been
previously published [12-14]. Here, we briefly described
the model structure and methods for adapting the model
to Brazil.
Model structure
The model has demographic and epidemiologic compo-
nents. The population is divided into sex and 23 age
groups to simulate demographic characteristics of the
population. Individuals die at sex- and age-specific rates
within each group, and individuals are born into the
youngest age group at a rate that balances mortality.
Each group is further stratified into three sexual activity
groups (low, medium, and high rates of sexual partner
change). The model accommodates general patterns of
mixing between age and sexual activity group. The epi-
demiologic component of the model simulates hetero-
sexual transmission of HPV-types 6/11/16/18 and
progression to cervical intraepithelial neoplasia (CIN)
grades 1, 2, and 3, cervical cancer, and genital warts. The
population is divided into epidemiologic compartments
according to the host's susceptibility to infection or the
host's status with respect to infection, immunity, disease,
screening, and treatment. All model simulations were
conducted in MathematicaW (Wolfram Research, Cham-
paign, IL, USA).
Model parameters
Model parameters regarding the natural history of HPV
6/11/16/18 infections and diseases, as well as diagnostic
characteristics were based on a previous literature review
[12]. Assuming that the natural history parameters are
similar, we kept the same parameter values used in the
U.S. model for Brazil. For model parameters for demo-
graphics, sexual behaviors, and clinical management of
HPV-related diseases, we conducted a comprehensive
literature review to obtain data for Brazil (Table 1)
[15-21]. The information collected for clinical manage-
ment of HPV-related diseases were age-specific cervical
cytologic screening and hysterectomy rates and age and
stage-specific cervical cancer mortality rates. When data
from Brazil were not available, we used data from an-
other country from the same region of the world. Based
on the recent literatures, we assumed that approximately
70% of targeted women would receive regular cervical
cytologic screening with specific annual screening rates
by age (Table 1). We also assumed that that the current
screening practice would remain the same throughout
the 100 year time horizon.Vaccine strategies and characteristics
We examined the health and economic impacts of three
different scenarios: 1) no vaccination, 2) routine vaccin-
ation of 12-year-old females, and 3) routine vaccination of
12-year-old females with a catch-up vaccination of 12 to
26-year-old females. Assuming that the national vaccin-
ation program will be school-based, routine vaccination
coverage was assumed to gradually cover 85% of girls by
12 years of age. We assumed that a catch-up program
among women 12 to 26 years of age would gradually in-
crease to cover 95% by 26 years of age. All vaccinated
women were assumed to complete a three-dose regimen.
We assumed the duration of vaccine protection to be life-
long. We also examined a 20-year duration of protection
in a sensitivity analysis. We estimated the cost of vaccin-
ation using the Pan American Health Organization
(PAHO) vaccine acquisition cost per dose in 2011
(US$15.15 per dose). We assumed a total cost of the
three vaccine series to be R$72.72 (US$45.45). The
model incorporates the vaccine efficacy from the
most recent clinical trials [12].
Economic data and health utility parameters
Costs were estimated from the perspective of the health-
care system in Brazil. The costs of cytology screening
and diagnosis were based on the official value reim-
bursed by the public health care in Brazil (Table 2) [22].
The costs associated with treatment of genital wart,
CIN, and cervical cancer cases are based on published
data [7,22]. Quality-adjusted life years (QALYs) were
estimated based on health utilities. Because the health
utility data were not available from Brazil, we used the
same health utility values from the U.S. [12]. Total
QALYs were estimated by weighting survival time by the
quality of life weights associated with each health state.
We examined the cost-effectiveness of introducing HPV
vaccination over a time horizon of 100 years. Costs and
QALYs were discounted at 3%.
Model simulations and validation
Model validation of the natural history component of
the U.S. model has been described previously. We
assessed the predictive validity of the model by compar-
ing the model outputs and observed epidemiological
data regarding cervical cancer incidence and mortality.
Age-standardized incidence rate of cervical cancer was
19.2 per 100,000 women per year and cervical cancer
mortality rate was 7.3 per 100,000 women per year in
Brazil [6,23]. Assuming that 70.7% of cervical cancer is
attributable to HPV-types 16 and 18, the HPV16/18-
related cervical cancer rate is estimated to be 13.6 per
100,000 women per year and the HPV16/18-related cer-
vical cancer mortality rate is estimated to be 5.2 per
100,000 per year [24]. The model projected an incidence
Table 1 Demographic, sexual behavior, cervical cancer
screening, and disease model parameters
Parameter Estimate Source
Demographic variables
Total population size 203,429,773 [15]
Annual all-cause mortality rate
by sex and age
(Data not shown) [16]
Sexual behavior variables
Annual mean number of sexual
partners by sex
Male Female [17]
15-19 yrs 1.65 1.29
20-24 yrs 1.89 1.07
25-34 yrs 1.40 1.06
35-44 yrs 1.22 0.98
45-59 yrs 1.15 0.79
Screening variables
Female
Cervical cancer screening rate,
% past 3 years
70 [18-20]
Cervical cancer screening rate,
% past year
[18]
<20 yrs 0.0
20-29 yrs 26.0
30-34 yrs 30.3
35-39 yrs 32.6
40-44 yrs 30.8
45-49 yrs 30.0
50-54 yrs 28.6
55-69 yrs 26.4
>70 yrs 10.0
Disease variables
Cervical cancer mortality rates, per year [21]
Localized cervical cancer
<40 yrs 0.135
40-49 yrs 0.066
50-59 yrs 0.090
60-69 yrs 0.100
>70 yrs 0.130
Regional cervical cancer
<40 yrs 0.202
40-49 yrs 0.100
50-59 yrs 0.136
60-69 yrs 0.150
>70 yrs 0.195
Distant cervical cancer
<40 yrs 0.808
40-49 yrs 0.399
50-59 yrs 0.543
Table 1 Demographic, sexual behavior, cervical cancer
screening, and disease model parameters (Continued)
60-69 yrs 0.602
>70 yrs 0.780
Population level hysterectomy rates, % per year
< 25 yrs 0.01
25-29 yrs 0.03
30-34 yrs 0.12
35-39 yrs 0.36
40-44 yrs 0.67
45-54 yrs 0.58
55-69 yrs 0.20
>70 yrs 0.20
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women per year and HPV16/18-related cancer mortality
of 5.0 per 100,000 per year. Data regarding the incidence
rates of genital warts and CIN were limited [25-27]. The
model projected overall incidence of HPV6/11-related
genital warts to be 165 per 100,000 per year. The
observed overall incidence of genital warts reported in
other parts of the world ranged from 100 to 200 epi-
sodes per 100,000 per year, with approximately 90% of
cases attributable to HPV6/11 [28-30].
Sensitivity analysis
The previous analysis in the U.S model has identified
the most influential parameters [12]. Based on the previ-
ous findings, we conducted a one-way sensitivity analysis
on parameters that incorporates different values for
duration of vaccine protection, costs of vaccine series,
vaccine coverage rates, HPV-related disease cost, and
discounting. We also examined a scenario assuming no
quality of life adjustments. In addition, we examined aTable 2 Cost of diagnosis and treatment of HPV-related
diseases
Parameter R$ US$ References
Genital warts-Female 94 59 [22]
Genital warts-Male 114 71 [22]
Cervical cancer screening and visit 17 11 [22]
Colposcopy 3 2 [22]
Biopsy 24 15 [22]
CIN1 episode-of-care 175 109 [22]
CIN2 episode-of-care 534 334 [22]
CIN3 episode of care 534 334 [22]
Localized cervical cancer 7769 4856 [7]
Regional cervical cancer 6520 4075 [7]
Distant cervical cancer 6520 4075 [7]
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Finally, we examined a pessimistic scenario that assumed
20 years of vaccine protection, low HPV-related disease
cost (decreased by 25%), and high health utility values
(0.97 for HPV-related disease).
Results
Health impact of HPV vaccination
The model projected that routine quadrivalent HPV
vaccination of 12-year-old girls will reduce the incidence
rate of HPV16/18-related cervical cancer by 59% at year
50 and by 97% at year 100 (Figure 1). The HPV16/18-
related cervical cancer mortality rate was also projected
to decline by 97% at year 100. The routine vaccination
of 12-year-old girls in combination with a catch-up vac-
cination of 12 to 26-year-old women will achieve greater
and earlier reduction in the number of cumulative cases
and deaths from cervical cancer than the routine vacci-
nation. Routine vaccination in combination with a
catch-up vaccination will reduce the incidence rate of
HPV16/18-related cervical cancer by 71% at year 50 and
by 99% at year 100. We estimated that routine vaccin-
ation in combination with a catch-up vaccination could
prevent 162,769 cumulative cases of cervical cancer by
year 50 and 795,693 cases by year 100 (Table 3). Routine
vaccination in combination with a catch-up vaccination
could prevent 47,802 cumulative deaths from cervical
cancer by year 50 and 278,283 deaths by year 100.
Our model projected that the HPV vaccination
program will reduce the incidence rates of genital warts
among women and men, and CIN2/3 before it reduces
the incidence rate of cervical cancer (Figure 1). The
model projected that routine vaccination of 12-year-old
girls will reduce the incidence of HPV6/11-related geni-
tal warts among females by 94%, HPV6/11/16/18-related
CIN1 by 98%, and HPV16/18-related CIN2/3 by 98% at
year 100. Through reducing HPV6/11 infections, routine
female vaccination could also provide indirect benefits
to men by reducing the incidence of genital warts by
70% at year 100. Compared to routine vaccination, rou-
tine vaccination in combination with a catch-up vaccin-
ation could result in earlier and greater reduction in the
cumulative cases of genital warts, CIN1, and CIN2/3
(Table 3). Routine vaccination in combination with a
catch-up vaccination could avoid 508,433 cumulative
cases of genital warts among women and men in the
first 10 years and 3,872,287 cumulative cases in the first
25 years.
Economic impact of HPV vaccination
Routine vaccination program could avoid a total cost of
approximately R$1.74 billion (US$1.09 billion) from
HPV6/11/16/18-related diseases in the next 100 years,
while routine vaccination in combination with a catch-up vaccination program could avoid R$2.10 billion
(US$1.31 billion) in the next 100 years (discounted at
3%). We estimated that about 67.3% of the total avoided
costs from routine and a catch-up vaccination program
would be from cervical diseases and 32.7% would be
from genital warts.
The incremental cost-effectiveness ratio (ICER) for
routine vaccination of 12-year-old girls’ strategy com-
pared to no vaccination strategy was R$350 per QALY
gained (US$219 per QALY gained; Table 4). Routine vac-
cination in combination with a catch-up vaccination of
12 to 26-year-old women was a more effective strategy
than the routine vaccination, with an ICER of R$720 per
QALY gained (US$450 per QALY gained).
We also conducted sensitivity analyses (Table 5). As-
suming no quality of life benefits, the ICER for routine
vaccination was R$404 (US$253) per year of life saved
and adding a catch-up vaccination was R$804 (US$503)
per year of life saved. When the benefits of preventing
HPV16/18-related cervical diseases were considered
alone, the ICER for routine vaccination was R$717 (US
$448) per QALY and adding a catch-up vaccination was
R$1117 (US$698) per QALY. When the assumed
duration of vaccine protection was reduced from lifelong
to 20 years, the ICER for routine and a catch-up vacci-
nation strategy was R$1049 (US$656) per QALY gained
compared to no vaccination. Cost of vaccines and
discounting rate also influenced the results. Finally,
when we examined the pessimistic scenario, we found
that ICER comparing routine and a catch-up vaccination
versus no vaccination was R$1596 (US$998) per QALY
gained.
Discussion
Our study demonstrates that quadrivalent HPV female
vaccination can substantially reduce the burden of
cervical diseases and genital warts in Brazil. The major
advantage of our analytic approach is the use of trans-
mission dynamic model that incorporates the direct and
indirect benefits of vaccination while evaluating effec-
tiveness at the population level over time. We found that
the routine vaccination of 12-year-old girls in combi-
nation with a catch-up vaccination of 12 to 26-year-old
women can be a cost-effective strategy that can achieve
earlier and greater reduction in HPV-related diseases
than the routine vaccination. Routine vaccination in
combination with a catch-up vaccination could prevent
approximately 163,000 cases of cervical cancer, 48,000
deaths from cervical cancer, 2.3 million cases of CIN2/3,
and 11.4 million genital warts in the next 50 years.
The World Health Organization considers an inter-
vention to be "very cost-effective" when its incremental
cost-effectiveness ratio is below GDP per capita [31]. We
found that the incremental cost-effectiveness ratios for
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Figure 1 (See legend on next page.)
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Figure 1 The incidence rates of HPV16/18-related cervical cancer, HPV16/18-related CIN2/3, and HPV6/11-related genital warts among
females and males by vaccination strategy during the next 100 years. We assumed that approximately 71% of cervical cancer cases were
attributable to HPV 16 and 18, and 90% of genital warts cases were attributable to HPV 6 and 11 in Brazil.
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$450 per QALY gained, which fell below a GDP per
capita (US$10,710 in Brazil). In order to address
uncertainty of the parameters, we conducted extensive
one-way sensitivity analyses. For an example, duration of
protection remains uncertain. Even when we decreased
the duration of vaccine protection to 20 years, we found
that the HPV vaccination was cost-effective especially
the vaccination strategy that included a catch-up vaccin-
ation. Four prior studies examined the cost-effectiveness
of HPV vaccination in Brazil [7-10]. Goldie et al. (2007)
used individual-based stochastic models and showed that
routine vaccination would cost I$120 to I$820 per year
of life saved [7]. Kim et al. (2007) also found vaccination
to be cost-effective using dynamic models [8]. Using the
similar individual-based dynamic model by Kim et al.,
Vanni et al. (2012) recently found that the ICER for the
quadrivalent HPV vaccination that incorporated the be-
nefits of preventing genital warts to be US$255/QALY
assuming similar cost of vaccination as ours ($55 for a
total cost of vaccinating woman) with discounting at 5%
[10]. Colantonio et al. (2009) used Markov models and
found the ICER to be US$10,200 per QALY assuming
US$210 for a total cost for vaccinating woman [9].
Higher ICER results may be because Colantonio et al.
(2009) assumed higher vaccine cost than ours and used
cohort model that did not take into account of herd im-
munity. In spite of differences in the model structure
and assumptions about model parameters regarding nat-
ural history of HPV disease, vaccine property, health
utilities, and costs, all studies consistently found HPV
vaccination of females to be cost-effective in Brazil.
Contrary to most previous studies, we incorporated
the potential impact of vaccination on HPV6/11-related
genital warts. The quadrivalent HPV vaccine wasTable 3 Estimated cumulative cases of HPV-types 6/11/16/18-
year-old girls or routine vaccination combined with a catch-u
HPV-related diseases Routine vaccination
10 years 25 years 50 years
Cervical cancer 22 6,449 118,825
Cervical cancer deaths 3 1,296 33,698
CIN1 3,797 132,541 763,332
CIN2/3 4,412 250,896 1,829,778
Genital warts among women 117,260 1,523,777 5,235,130
Genital warts among men 70,649 1,173,031 4,314,599projected to reduce the incidence of genital warts in a
short period of time. This is consistent with a rapid
decline in the incidence of genital warts observed among
young women in Australia where vaccination has been
already implemented [32,33]. Although numerous stud-
ies from North America and Europe have shown that
HPV female vaccination is generally cost-effective, our
incremental cost-effectiveness ratios in Brazil were lower
than that in those countries [34-36]. Despite the low
cost of treatment for HPV-related diseases, quadrivalent
HPV vaccination in Brazil can be a cost-effective inter-
vention, because it can prevent substantial burden of
cervical cancer and genital warts.
Our model projected that HPV vaccination could
prevent approximately 163,000 cases of cervical cancer,
48,000 deaths from cervical cancer and 11.4 million geni-
tal warts in the next 50 years. Many women who suffer
from cervical cancer are young and actively caring for
their families and it could have devastating consequences
to their children and families who lose their mothers.
Because we cannot incorporate such effects in cost-
effectiveness analysis, our results likely underestimate the
potential societal benefits of vaccination. Moreover, our
model projected the substantial impact of HPV vaccin-
ation on genital warts, which may have long-term psycho-
logical and/or physical consequences and profoundly
affect patient's quality of life [29,37]. For example, even
after treatment, women and men may experience anxiety
of recurrence or persistence of genital warts [29]. Redu-
cing cases of genital warts will not only reduce healthcare
utilization but will also free up resources for diagnosis and
treatment of other diseases.
Our study has several limitations. Although the model
was built on available current knowledge on HPV
diseases, more studies are needed to understand therelated disease prevented with routine vaccination of 12
p vaccination of 12- to 26-year-old women in Brazil
Routine and a catch-up vaccination
100 years 10 years 25 years 50 years 100 years
712,067 117 12,954 162,769 795,693
247,572 15 2,700 47,802 278,283
2,437,178 14,744 218,133 943,965 2,674,632
6,498,426 18,948 435,052 2,301,481 7,135,912
13,151,591 318,735 2,180,661 6,177,401 14,459,056
11,031,658 189,698 1,691,626 5,199,269 12,650,796
Table 4 Cost-effectiveness analysis of HPV types 6/11/16/18 vaccination in Brazil
Strategies1 Discounted total Incremental
Costs (R$) /person QALYs /person Costs (R$) /person QALYs /person Costs (R$) /QALYs Costs (US$) /QALYs
No vaccination 90.64 27.03841 - - - -
Routine vaccination 94.38 27.04912 3.74 0.01071 350 219
Routine and a catch-up
vaccination
96.09 27.05150 1.71 0.00238 720 450
1 Strategies are listed in order of increasing effectiveness.
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http://www.biomedcentral.com/1471-2334/12/250natural history of HPV. Detailed data specific to Brazil,
such as healthcare seeking behaviors and age- and stage-
specific mortality rates from cervical cancer, were
limited. Because health utility data were not available
from Brazil, we used the health utility values from the
U.S. Our model does not incorporate demographic
changes in the future, such as population growth. Our
model did not account for any temporal changes in
screening practice or possible introduction of new
screening methods such as HPV DNA testing. As some
researchers have examined, it is important to consider
screening changes in future research [38,39]. Although
the coverage rate of HPV vaccination is unknown, weTable 5 Incremental cost-effectiveness ratio (ICER) for
sensitivity analyses
Parameter Routine
vaccination
Routine and
a catch-up
vaccination
US$ per QALYs US$ per QALYs
Base case 219 450
Cost per year of life saved
(no quality of life adjustments)
253 503
HPV16/18-related cervical
diseases only
448 698
Duration of vaccine
protection = 20 years
Dominated1 656
Vaccine coverage= 50% for
routine and 60% for catch-up
106 250
Vaccine coverage= 95% for
routine and 98% for catch-up
258 425
High cost of vaccine series
(increased by 25%)
406 686
High cost of treating HPV-related
disease (increased by 25%)
86 326
Low cost of treating HPV-related
disease (decreased by 25%)
350 573
Discounted at 0% Cost saving Cost saving
Discounted at 5% 900 1201
Pessimistic scenario2 Dominated1 998
1 A strategy is “weakly” dominated if a more effective strategy has a lower
incremental cost-effectiveness ratio.
2 Pessimistic scenario assumes low HPV-related disease cost (decreased by
25%), 20 years of vaccine protection, and high health utilities (0.97 for HPV-
related disease).assumed high coverage because Brazil has a strong na-
tional immunization program that has achieved high
(>90%) immunization coverage in many currently sched-
uled vaccines [40].
We only assessed fit of the adapted model by assessing
overall incidence of cervical cancer and did not assess age-
specific data. We did not employ calibration method that
identifies parameters that best predict observed data.
Moreover, because of the complexity of the model, it was
not feasible to conduct probabilistic sensitivity analysis.
Our projected incidence rates of HPV6/11-related
genital warts were comparable to the previously reported
incidence rates in other parts of the world [28-30]. A
survey conducted by the Ministry of Health in Brazil
found that 5.7% of pregnant women reported having a
history of clinical diagnosis of genital warts [25]. How-
ever, data regarding the incidence of genital warts in the
general population in Brazil were not available.
HPV vaccine may have cross-protection against non-
vaccine, oncogenic HPV-types; however, the duration
and efficacy of the cross-protection remains uncertain
[41]. If this additional benefit of vaccine was considered,
we would have more favorable cost-effectiveness. We did
not consider the potential benefits of HPV vaccination
on other HPV-related diseases such as vulvar, vaginal,
anal, head and neck, and penile cancers, and recurrent
respiratory papillomatoses. Previous studies in the U.S.
included these diseases and showed an improvement in
incremental cost-effectiveness ratios [12,42]. The HPV
vaccination of males could also be important because it
may prevent some of these cancers and genital warts.
Conclusion
In conclusion, our study demonstrates that quadrivalent
HPV vaccination can substantially reduce the burden of
cervical diseases and genital warts in Brazil. Our model
results show that HPV vaccination of females, particu-
larly routine vaccination of 12-year-old girls in combin-
ation of a catch-up vaccination of 12 to 26-year-old
women, can be a cost-effective intervention in Brazil.
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